Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Net Income (2023 - 2025)

Historic Net Income for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$31.8 million.

  • Tonix Pharmaceuticals Holding's Net Income fell 10102.29% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.7 million, marking a year-over-year increase of 3109.61%. This contributed to the annual value of -$136.7 million for FY2024, which is 3920.11% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Net Income stood at -$31.8 million for Q3 2025, which was down 10102.29% from -$27.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Net Income registered a high of -$15.8 million during Q3 2024, and its lowest value of -$77.3 million during Q2 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Net Income value was -$27.3 million (recorded in 2023), while the average stood at -$29.7 million.
  • Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's Net Income was 6462.14% (2025), while the steepest drop was 10102.29% (2025).
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Net Income stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then crashed by 41.62% to -$31.8 million in 2025.
  • Its Net Income stands at -$31.8 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$16.1 million for Q1 2025.